Clinical trials: Letrozole
Breast Cancer
Letrozole After Tamoxifen in Treating Women With Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen.
- Trial name
- NCT00003140
- Testing
- letrozole
- Where
- 57 sites in Canada, United Kingdom
- Volunteers
- 5,187 people
- Sponsor
- NCIC Clinical Trials Group
McCune Albright Syndrome, Polyostotic Fibrous Dysplasia
Effects of Letrozole on Precocious Puberty Due to McCune Albright Syndrome
This study will test the safety and effectiveness of letrozole in treating precocious (early) puberty in girls with McCune-Albright syndrome (MAS).
- Conditions
- McCune Albright Syndrome, Polyostotic Fibrous Dysplasia, Precocious Puberty
- Trial name
- NCT00006174
- Testing
- Letrozole
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Metastatic Breast Cancer
Capecitabine in Combination With Aromatase Inhibitor Versus Aromatase Inhibitors, in Hormonal Receptor Positive Recurrent or Metastatic Breast Cancer Patients, Randomized Controlled Study
Women with recurrent or metastatic breast cancer who are hormone receptor positive are candidates for first line hormonal therapy including aromatase inhibitors.
- Trial name
- CONCEPT (NCT04012918)
- Testing
- Capecitabine plus aromatase inhibitor, A.I.
- Where
- Egypt
- Volunteers
- 124 people
- Sponsor
- Ain Shams University
Bone Loss, Breast Cancer
Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every…
- Trial name
- NCT00171340
- Testing
- Zoledronic acid, Letrozole
- Where
- 106 sites in Argentina, Australia and 26 more
- Volunteers
- 1,065 people
- Sponsor
- Novartis Pharmaceuticals
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
This phase II trial studies the side effects and how well letrozole and imatinib mesylate work in treating postmenopausal participants with estrogen or progesterone positive breast cancer that has spread to other places in the…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive
- Trial name
- NCT00338728
- Testing
- Imatinib Mesylate, Letrozole
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer
The purpose of this study is to compare the rate of disease free survival (DFS) and distant disease free survival (DDFS) at 5 years in postmenopausal women with hormone receptor and lymph node positive breast cancer randomized…
- Trial name
- LEANEX (NCT00902954)
- Testing
- anastrozole, letrozole, exemestane
- Where
- China
- Volunteers
- 540 people
- Sponsor
- Fudan University
Infertility, Female
Different Induction Protocols in PCOS After Clomiphene Citrate Failed Pregnancy in Non-IVF Cycles
The aim of this study will be to compare between 4 different induction protocols in women who: 1. Failed to achieve ovulation after clomiphene citrate treatment at a dose of 150mg daily (if the patient can tolerate this dose) for…
- Trial name
- NCT05362799
- Testing
- Letrozol (Femara, Novartis), Letrozol (Femara, Novartis) combined with Metformin (Cidophage 500 mg, Cid Pharmaceuticals, Egypt), highly purified lyophilized Uroffollitropin (Fostimon, IBSA Institut Biochimique SA, Lugano, Switzerland)
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- Menoufia University
Breast Cancer
Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00403182
- Testing
- chemotherapy, letrozole
- Where
- 9 sites in Germany
- Sponsor
- Technical University of Munich
Ovarian Stimulation
Antagonist/Letrozole in Poor Responders
Failure to respond to controlled ovarian hyperstimulation (COH) is still a major concern in assisted reproduction and there is no consensus on the ovarian stimulation choice regime for poor responders.
- Trial name
- NCT00823004
- Testing
- letrozole, oral contraceptive (Marvelone), GnRH agonist (buserelin)
- Where
- Iran
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Yazd Research & Clinical Center for Infertility
Breast Cancer
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the…
- Trial name
- NCT00290745
- Testing
- letrozole, tamoxifen citrate, conventional surgery
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of California, San Francisco
Breast Cancer
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane, letrozole, or anastrozole, may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00265759
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in United States
- Volunteers
- 622 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Idiopathic Short Stature
Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
When treating very short children in puberty we are time-limited, as sex hormones cause the growth plates to fuse and growth to end.
- Trial name
- ThrasherAI (NCT01248416)
- Testing
- Aromatase Inhibitor, Growth Hormone, Aromatase Inhibitor and Growth Hormone
- Where
- 4 sites in United States, Chile
- Volunteers
- 76 people
- Sponsor
- Nemours Children's Clinic
Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
This phase II trial studies how well abemaciclib works in treating patients with ovarian or endometrial cancer that has an activation of the CDK4/6 pathway and that has come back (recurrent).
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT04469764
- Testing
- Abemaciclib, Anastrozole, Letrozole
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Metastatic Breast Cancer, HER2-negative Breast Cancer
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
- Conditions
- Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
- Trial name
- TRACY-1 (NCT06590857)
- Testing
- RYZ101, Standard of Care Endocrine Therapy
- Where
- 31 sites in United States, Canada and 1 more
- Volunteers
- 64 people
- Sponsor
- RayzeBio, Inc.
Medical; Abortion, Fetus
Comparison of Rate of Complete Abortion Between Letrozole Plus Misoprostol vs Misoprostol Alone
Comparison of rate of complete abortion between Letrozole plus Misoprostol versus Misoprostol alone in first trimester pregnancy
- Trial name
- NCT05940233
- Testing
- Letrozole
- Where
- Thailand
- Volunteers
- 70 people
- Sponsor
- Queen Savang Vadhana Memorial Hospital, Thailand
Breast Cancer
Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897065
- Testing
- microarray analysis, polymerase chain reaction, protein expression analysis
- Where
- United States
- Volunteers
- 957 people
- Sponsor
- Massachusetts General Hospital
ER+ Breast Cancer
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
The addition of entinostat to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor.
- Trial name
- NCT00828854
- Testing
- Entinostat, Aromatase Inhibitor (AI) Therapy
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Syndax Pharmaceuticals
Breast Cancer, Letrozole
Safety and Efficacy Study of Femara(Letrozole) as an Extended Adjuvant Treatment in Breast Cancer Patients
Title of study: An observational, multicenter study on the safety and efficacy of Femara® (Letrozole) as an extended adjuvant treatment in breast cancer patients who completed adjuvant Tamoxifen or Toremifen treatment Objectives…
- Trial name
- NCT01249456
- Where
- South Korea
- Volunteers
- 392 people
- Sponsor
- Novartis Pharmaceuticals
Termination of Early Pregnancy in Scarred Uterus
Termination of Early Pregnancy in Scarred Uterus With Lletrozole and Misoprostol Compared to Misoprostol Alone
Termination of early pregnancy in scarred uterus with letrozole and misoprostol compared to Misoprostol alone
- Trial name
- NCT05067309
- Testing
- Letrozole 2.5mg
- Where
- 2 sites in Egypt
- Volunteers
- 1 people
- Sponsor
- Ahmed Elsayed Aref
Neoplasm Malignant
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen
Primary Objective: The purpose of this study was to determine the long term safety and tolerability of SAR245408 and SAR245409 as a monotherapy or as part of a combination regimen in participants who were benefiting from…
- Trial name
- NCT01587040
- Testing
- SAR245408, SAR245409
- Where
- 21 sites in United States, Belgium and 2 more
- Volunteers
- 61 people
- Sponsor
- Sanofi